Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Uterine Cancer Treatment
Topotecan evaluated for treatment of uterine carcinosarcoma
September 22nd, 2005
Topotecan was recently evaluated for treatment of uterine carcinosarcoma. Investigators in the United States conducted a study "To estimate the antitumor activity of topotecan in patients with persistent or recurrent carcinosarcoma (malignant mixed mullerian tumors) of the uterus and to determine the nature and degree of toxicity of topotecan in this cohort of patients." "Eligible patients had measurable advanced or recurrent carcinosarcoma of the uterus," wrote D .S. Miller and colleagues. "Topotecan at a target dose of 1.5 mg/m2 was administered IV daily for 5 days, every 3 weeks, until progression of disease or adverse affects...
Source: Women's Health Weekly (2005-09-22)
|
